• Department of Clinical Pharmacy, West China Hospital, Sichuan University, Chengdu, 610041, P.R.China;
XU Ting, Email: tingx2009@163.com
Export PDF Favorites Scan Get Citation

ObjectivesTo systematically review the efficacy and safety of bevacizumab combined with STUPP regimen for newly diagnosed glioblastoma.MethodsPubMed, EMbase, the Cochrane Library, CBM, CNKI, VIP and WanFang Data databases were searched to obtain randomized controlled trials (RCTs) of bevacizumab combined with STUPP regimen for newly diagnosed glioblastoma patients from inception to September 2017. Two reviewers independently screened literature, extracted data and assessed the risk of bias of included studies. Meta-analysis was then performed using RevMan 5.3 software.ResultsA total of 6 RCTs involving 2 835 patients were included. The results of meta-analysis showed that: the bevacizumab combined with STUPP regimen group was superior to the control group on PFS (HR=0.69, 95%CI 0.62 to 0.77, P<0.000 01). But the adverse events rate at the three and above three levels was significantly higher than the control group (P<0.05).ConclusionsCurrent evidence shows that bevacizumab combined with STUPP regimen for newly diagnosed glioblastoma can significantly prolong the PFS. The treatment group performs not as well as the control group on adverse event rate. Due to the limited quality and quantity of the included studies, more high-quality studies are required to verify above conclusions.

Citation: CHEN Zhaoyan, TIAN Fangyuan, ZHAN Mei, XU Ting. Efficacy and safety of bevacizumab combined with STUPP regimen for newly diagnosed glioblastoma: a meta-analysis. Chinese Journal of Evidence-Based Medicine, 2018, 18(5): 470-475. doi: 10.7507/1672-2531.201710122 Copy

  • Previous Article

    Efficacy and safety of application of enhanced recovery after pancreaticoduodenectomy surgery (ERAS): a meta-analysis
  • Next Article

    Efficacy and safety of Orlistat for obese patients with cardiovascular risk: a meta-analysis